INS and type 2 diabetes mellitus: At study entry 14(88%) T2DM subjects were receiving metformin, 4 (25%) incretin-based therapies (GLP-1 analogs or DPP4 inhibitors), 3 (18%) sulfonylureas, 2(12%) thiazolidinediones and 2(12%) basal insulin.